Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed |
|---|---|---|
|
Imax Corp
13G/A
Amendment 1
IMAX · 45245E109
|
4.99% |
6/3/2026
Event 5/31/2026
|
|
Imax Corp
13G
IMAX · 45245E109
|
5.0% |
5/5/2026
Event 4/30/2026
|
|
Bicycle Therapeutics PLC
13G/A
Amendment 3
BCYC · 088786108
|
0% |
3/4/2026
Event 2/28/2026
|
|
Bicycle Therapeutics PLC
13G/A
Amendment 2
BCYC · 088786108
|
0% |
3/3/2026
Event 12/31/2025
|
|
Bicycle Therapeutics PLC
13G/A
Amendment 2
BCYC · 088786108
|
0% |
3/3/2026
Event 12/31/2025
|
|
Bicycle Therapeutics PLC
13G/A
Amendment 1
BCYC · 088786108
|
6.0% |
2/11/2026
Event 12/31/2025
|
|
Ascendis Pharma A/S
13G/A
Amendment 4
ASND · 04351P101
|
8.5% |
2/11/2026
Event 12/31/2025
|
|
Flywire Corp
13G/A
Amendment 1
FLYW · 302492103
|
0% |
3/5/2025
Event 2/28/2025
|
|
Ascendis Pharma A/S
13G/A
Amendment 3
ASND · 04351P101
|
9.2% |
2/11/2025
Event 12/31/2024
|
|
Innoviva, Inc.
13G/A
Amendment 2
INVA · 45781M101
|
0% |
2/11/2025
Event 12/31/2024
|
|
Flywire Corp
13G
FLYW · 302492103
|
5.3% |
2/11/2025
Event 12/31/2024
|
|
Bicycle Therapeutics PLC
13G
BCYC · 088786108
|
5.5% |
2/11/2025
Event 12/31/2024
|
|
Ascendis Pharma A/S
13G/A
Amendment 2
ASND · 04351P101
|
9.2% |
2/10/2025
Event 12/31/2024
|